Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
27.15 USD -1.42% Intraday chart for Supernus Pharmaceuticals, Inc. +2.18% -6.19%
May. 23 Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study MT
May. 23 Transcript : Supernus Pharmaceuticals, Inc. - Special Call

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study
MT
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M
MT
Supernus Pharmaceuticals, Inc. Seeks M&A
CI
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024
CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America
CI
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
RE
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M
MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents
MT
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada
MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada
MT
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
CI
Knight Therapeutics in Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
MT
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling
MT
US Consumer group seeks stronger warnings on Botox, similar treatments
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
  5. Highlights